Immune restoration under HAART in patients chronically infected with HTV-1: Diversity of T, B, and NK immune responses

Viral Immunology

Volumn 19, Issue 2, 2006, Pages 267-276

  Le Guillou Guillemette, H ^a   Renier, G ^a   Vielle, B ^a   Abgueguen, P ^a   Chennebault, J M ^a   Lunel, F ^a   Payan, C ^a,b  

^a ANGERS UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ DE BRETAGNE OCCIDENTALE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; CD8 ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ANTIBODY DETECTION; ARTICLE; AVIDITY INDEX; B LYMPHOCYTE; BINDING AFFINITY; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL ARTICLE; EVALUATION; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNE RESTORATION; IMMUNE SYSTEM; INNATE IMMUNITY; MALE; MEMORY CELL; NATURAL KILLER T CELL; OPPORTUNISTIC INFECTION; PROSPECTIVE STUDY; REFERENCE VALUE; T LYMPHOCYTE SUBPOPULATION; TREND STUDY; VIRUS LOAD;

ADULT; ANTIBODY AFFINITY; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; B-LYMPHOCYTES; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CHRONIC DISEASE; FEMALE; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOGLOBULIN G; KILLER CELLS, NATURAL; MALE; MIDDLE AGED; T-LYMPHOCYTES; TREATMENT OUTCOME;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 33745906822     PISSN: 08828245     EISSN: None     Source Type: Journal    
DOI: 10.1089/vim.2006.19.267     Document Type: Article

References (30)

1. Al-Harthi, L., J. Voris, B. K. Patterson, S. Becker, J. Eron, K. Y. Smith, R. D'Amico, D. Mildvan, J. Snidow, B. Pobiner, L. Yau, and A. Landay. 2004. Evaluation of the impact of highly active antiretroviral therapy on immune recovery in antiretroviral naive patients. HIV Med. 5:55-65.
2. Autran, B., G. Carcelain, T. S. Li, C. Blanc, D. Mathez, R. Tubiana, C. Katlama, P. Debre, and J. Leibowitch. 1997. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 277:112-116.
3. Barao, I., and J. L. Ascensao. 1998. Human natural killer cells. Arch Immunol Ther Exp (Warsz); 46:213-229.
4. Becker, Y. 2004. The changes in the T helper 1 (Th1) and T helper 2 (Th2) cytokine balance during HIV-1 infection are indicative of an allergic response to viral proteins that may be reversed by Th2 cytokine inhibitors and immune response modifiers-a review and hypothesis. Virus Genes 28:5-18.
5. Binley, J. M., A. Trkola, T. Ketas, D. Schiller, B. Clas, S. Little, D. Richman, A. Hurley, M. Markowitz, and J. P. Moore. 2000. The effect of highly active antiretroviral therapy on binding and neutralizing antibody responses to human immunodeficiency virus type 1 infection. J Infect Dis 182:945-9.
6. De Milito, A. 2004. B lymphocyte dysfunctions in HIV infection. Curr HIV Res 2:11-21.
7. De Milito, A., C. Morch, A. Sonnerborg, and F. Chiodi. 2001. Loss of memory (CD27) B lymphocytes in HIV-1 infection. Aids 15:957-64.
8. Erb, P., M. Battegay, W. Zimmerli, M. Rickenbach, and M. Egger. 2000. Effect of antiretroviral therapy on viral load, CD4 cell count, and progression to acquired immunodeficiency syndrome in a community human immunodeficiency virus-infected cohort. Swiss HIV Cohort Study. Arch Intern Med; 160:1134-40.
9. Fernandez-Cruz, E., S. Moreno, J. Navarro, B. Clotet, E. Bouza, J. Carbone, J. M. Pena, J. Perez Molina, D. Podzamczer, R. Rubio, I. Ocana, F. Pulido, P. Viciana, J. A. Maradona, R. Blazquez, C. Barros, C. Quereda, C. Rodriguez-Sainz, J. Gil, M. L. Abad, L. Diaz, C. Canto, M. A. Munoz, E. Ferrer, A. Jou, G. Sirera, M. Diaz, F. Lopez, J. M. Gatell, and J. Gonzalez-Lahoz. 2004. Therapeutic immunization with an inactivated HIV-1 Immunogen plus antiretrovirals versus antiretroviral therapy alone in asymptomatic HIV-infected subjects. Vaccine; 22:2966-73.
10. Finzi, D., M. Hermankova, T. Pierson, L. M. Carruth, C. Buck, R. E. Chaisson, T. C. Quinn, K. Chadwick, J. Margolick, R. Brookmeyer, J. Gallant, M. Markowitz, D. D. Ho, D. D. Richman, and R. F. Siliciano. 1997. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science; 278:1295-300.
11. Fleury, S., G. P. Rizzardi, A. Chapuis, G. Tambussi, C. Knabenhans, E. Simeoni, J. Y. Meuwly, J. M. Corpataux, A. Lazzarin, F. Miedema, and G. Pantaleo. 2000. Long-term kinetics of T cell production in HIV-infected subjects treated with highly active antiretroviral therapy. Proc Natl Acad Sci U S A; 97:5393-8.
12. Fondere, J. M., M. F. Huguet, H. Yssel, V. Baillat, J. Reynes, P. Van De Perre, and J. P. Vendrell. 2003. Detection of peripheral HIV-1-specific memory B cells in patients untreated or receiving highly active antiretroviral therapy. Aids; 17:2323-2330.
13. Fournier, A. M., V. Baillat, C. Alix-Panabieres, J. M. Fondere, C. Merle, M. Segondy, M. F. Huguet, J. Reynes, and J. P. Vendrell. 2002. Dynamics of spontaneous HIV-1 specific and non-specific B-cell responses in patients receiving antiretroviral therapy. Aids 16:1755-60.
14. Garcia, F., M. Plana, G. M. Ortiz, S. Bonhoeffer, A. Soriano, C. Vidal, A. Cruceta, M. Arnedo, C. Gil, G. Pantaleo, T. Pumarola, T. Gallart, D. F. Nixon, J. M. Miro, and J. M. Gatell. 2001. The virological and immunological consequences of structured treatment interruptions in chronic HIV-1 infection. Aids; 15:F29-40.
15. Gulick, R. M., J. W. Mellors, D. Havlir, J. J. Eron, A. Meibohm, J. H. Condra, F. T. Valentine, D. McMahon, C. Gonzalez, L. Jonas, E. A. Emini, J. A. Chodakewitz, R. Isaacs, and D. D. Richman. 2000. 3-year suppression of HIV viremia with indinavir, zidovudine, and lamivudine. Ann Intern Med 133:35-9.
16. Jacobson, M. A., H. Khayam-Bashi, J. N. Martin, D. Black, and V. Ng. 2002. Effect of long-term highly active antiretroviral therapy in restoring HIV-induced abnormal B-lymphocyte function. J Acquir Immune Defic Syndr; 31:472-7.
17. Le Guillou, H., A. Le Meur, S. Bourdon, M. Riou, J. Loison, P. Fialaire, J. M. Chennebault, S. Kouyoumdjian, and C. Payan. 2001. [Antibody avidity: use for the diagnosis of HIV early infection]. Ann Biol Clin (Paris); 59:41-7.
18. Letvin, N. L., and B. D. Walker. 2003. Immunopathogenesis and immunotherapy in AIDS virus infections. Nat Med; 9:861-6.
19. Li, T. S., R. Tubiana, C. Katlama, V. Calvez, H. Ait Mohand, and B. Autran. 1998. Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HTV-1 disease. Lancet; 351:1682-6.
20. Mansour, I., C. Doinel, and P. Rouger. 1990. CD16+ NK cells decrease in all stages of HIV infection through a selective depletion of the CD16+CD8+CD3- subset. AIDS Res Hum Retroviruses; 6:1451-7.
21. Moir, S., K. M. Ogwaro, A. Malaspina, J. Vasquez, E. T. Donoghue, C. W. Hallahan, S. Liu, L. A. Ehler, M. A. Planta, S. Kottilil, T. W. Chun, and A. S. Fauci. 2003. Perturbations in B cell responsiveness to CD4+ T cell help in HIV-infected individuals. Proc Natl Acad Sci USA 100:6057-62.
22. Montefiori, D. C., T. S. Hill, H. T. Vo, B. D. Walker, and E. S. Rosenberg. 2001. Neutralizing antibodies associated with viremia control in a subset of individuals after treatment of acute human immunodeficiency virus type 1 infection. J Virol 75:10200-7.
23. Morris, L., J. M. Binley, B. A. Clas, S. Bonhoeffer, T. P. Astill, R. Kost, A. Hurley, Y. Cao, M. Markowitz, D. D. Ho, and J. P. Moore. 1998. HIV-1 antigen-specific and -nonspecific B cell responses are sensitive to combination antiretroviral therapy. J Exp Med 188:233-45.
24. Papasavvas, E., G. M. Ortiz, R. Gross, J. Sun, E. C. Moore, J. J. Heymann, M. Moonis, J. K. Sandberg, L. A. Drohan, B. Gallagher, J. Shull, D. F. Nixon, J. R. Kostman, and L. J. Montaner. 2000. Enhancement of human immunodeficiency virus type 1-specific CD4 and CD8 T cell responses in chronically infected persons after temporary treatment interruption. J Infect Dis 182:766-75.
25. Pomerantz, R. J., and D. L. Horn. 2003. Twenty years of therapy for HIV-1 infection. Nat Med 9:867-73.
26. Pontesilli, O., S. Kerkhof-Garde, D. W. Notermans, N. A. Foudraine, M. T. Roos, M. R. Klein, S. A. Danner, J. M. Lange, and F. Miedema. 1999. Functional T cell reconstitution and human immunodeficiency virus-1-specific cell-mediated immunity during highly active antiretroviral therapy. J Infect Dis 180:76-86.
27. Riou, M., G. Renier, S. Mattman, P. Fialaire, J. Loison, J. M. Chennebault, and C. Payan. 2000. [Dynamic study of anti-HIV antibody avidity after cellular immunity restoration under antiretroviral treatment]. Ann Biol Clin (Paris); 58:715-20.
28. Scott-Algara, D., and P. Paul. 2002. NK cells and HIV infection: lessons from other viruses. Curr Mol Med 2:757-68.
29. Sirianni, M. C., L. Vincenzi, S. Topino, A. Giovannetti, F. Mazzetta, F. Libi, D. Scaramuzzi, M. Andreoni, E. Pinter, S. Baccarini, G. Rezza, P. Monini, and B. Ensoli. 2002. NK cell activity controls human herpesvirus 8 latent infection and is restored upon highly active antiretroviral therapy in AIDS patients with regressing Kaposi's sarcoma. Eur J Immunol 32:2711-20.
30. Suligoi, B., C. Galli, M. Massi, F. Di Sora, M. Sciandra, P. Pezzotti, O. Recchia, F. Montella, A. Sinicco, and G. Rezza. 2002. Precision and accuracy of a procedure for detecting recent human immunodeficiency virus infections by calculating the antibody avidity index by an automated immunoassay-based method. J Clin Microbiol 40:4015-20.